PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is also developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
Name | Title | Since | Age |
|---|---|---|---|
| Jan-Yau Hsu | Chairman | 2025 | - |
| Chien-Huang Lin | Independent Director | 2021 | - |
| Rui-Wen Wu | Representative Director | 2018 | - |
| Yi-Hui Lin | Representative Director | 2018 | - |
| Chih-Li Wang | Independent Director | 2019 | - |
| Ming-Feng Hou | Director | 2021 | - |
| Ming-Daw Chang | Independent Director | - | - |
| Wen-Hung Hsu | Representative Director | - | 59 |
| Ming-Shiang Wu | Representative Director | - | - |
| Pau-Chu Lo | Independent Director | 2025 | - |
| Wen-Ta Chiu | Independent Director | 2025 | - |